All In Biotech

Drug Trial Radar · NCT05848011

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 154 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

154

Actual

Start

Sep 28, 2023

Primary completion

Feb 19, 2026

Study completion Mar 16, 2026

Sponsor

Lead sponsor
MacroGenicsIndustry
Sponsor type
Industry
First posted
May 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether the amount of time before disease progression can be prolonged in participants with metastatic castration-resistant prostate cancer (MCRPC) who receive lorigerlimab in addition to the standard of care (SOC) of docetaxel and prednisone. About 150 participants with mCRPC will be enrolled. Participants will be randomized in a 2:1 ratio to receive lorigerlimab with docetaxel and prednisone (experimental arm) or docetaxel and prednisone alone (standard-of-care arm). Lorigerlimab+docetaxel or docetaxel will be administered intravenously (IV) in clinic on Day 1 of each 3-week cycle. Prednisone will be administered orally twice daily. Lorigerlimab will be administered for up to 35 cycles. Docetaxel and prednisone will be administered up to 10 cycles until treatment discontinuation criteria are met. Participants will undergo regular testing for signs of disease progression using computed tomography (CT) scans, magnetic resonance imaging (MRI) and prostate-specific antigen (PSA) blood tests. Participants will be asked to complete questionnaires about their health and well-being. Routine examinations and blood tests will be performed and evaluated by the study doctor. Participants who have disease progression standard-of-care arm have the option of continuing on the study to receive lorigerlimab monotherapy.

Conditions

  • Androgen-Independent Prostatic Cancer
  • Androgen-Independent Prostatic Neoplasms
  • Prostate Cancer Recurrent
  • Androgen-Insensitive Prostatic Cance
  • Androgen-Resistant Prostatic Cancer
  • Hormone Refractory Prostatic Cancer
  • Immunotherapy
  • Immune Checkpoint Inhibitor
  • Inhibitory Checkpoint Molecule

Interventions

  • lorigerlimabBiological

    Lorigerlimab is a DART® molecule that binds PD-1 and CTLA-4

  • docetaxelDrug

    Docetaxel Injection is a cytotoxic anticancer drug approved to treat prostate cancer

  • PrednisoneDrug

    A corticosteroid drug approved for use with docetaxel in the treatment of prostate cancer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median radiographic progression free survival (rPFS) determined by investigator review.Time frame: Every 9 weeks for the first year, followed by every 12 weeks for up to 3 more years

Locations

61 sites in 10 countries. Site status is shown where the registry gives one.

  • United Medical Group

    Miami, Florida

  • Orlando Health Cancer Institute

    Orlando, Florida

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Nebraska Cancer Specialists

    Grand Island, Nebraska

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • SUNY Upstate Medical University

    Syracuse, New York

  • MD Anderson Cancer Center

    Houston, Texas

  • START Mountain Region

    West Valley City, Utah

  • University of Virginia Health System Cancer Center

    Charlottesville, Virginia

  • Concord Repatriation General Hospital

    Concord, Australia

  • Peter MacCallum Cancer Centre

    North Melbourne, Australia

  • North Shore Private Hospital

    St Leonards, Australia

  • Westmead Hospital

    Westmead, Australia

  • Cliniques universitaires Saint-Luc (CUSL), Brussels

    Brussels, Belgium

  • UZ GENT

    Ghent, Belgium

  • Centre Hospital de l'Ardenne

    Libramont, Belgium

  • CHU de Liège

    Liège, Belgium

  • MHAT Dr. Tota Venkova

    Gabrovo, Bulgaria

  • Comprehensive Cancer Center

    Plovdiv, Bulgaria

  • UMHAT Sv. Ivan Rilski

    Sofia, Bulgaria

  • Institut Bergonie

    Bordeaux, France

  • Clinique Victor Hugo

    Le Mans, France

  • Centre Léon Bérard

    Lyon, France

  • Centre Antoine Lacassagne

    Nice, France

  • Institut Mutualiste Montsouris

    Paris, France

  • Centre Hospitalier Quimper

    Quimper, France

  • CHP Saint Grégoire

    Saint-Grégoire, France

  • Hia Begin

    Saint-Mandé, France

  • Hopital Foch

    Suresnes, France

  • Institut Gustave Roussy

    Villejuif, France

  • LTD High Tech Hosp Medcenter

    Batumi, Georgia

  • First University Clinic TSMU

    Tbilisi, Georgia

  • LTD Consilium Medulla

    Tbilisi, Georgia

  • Ltd Gidmedi

    Tbilisi, Georgia

  • LtD L.M.National Urology Center

    Tbilisi, Georgia

  • LTD MMT Hospital

    Tbilisi, Georgia

  • LTD Todua Clinic

    Tbilisi, Georgia

  • Onc. Scient. Research Center

    Tbilisi, Georgia

  • Przychodnia Lekarska KOMED

    Konin, Poland

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.